These innovative agents represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://flynnipnl470031.livebloggs.com/45786535/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide